Shire Launches Nationwide Adult ADHD Mobile Awareness Tour

PHILADELPHIA, May 12 Shire plc (LSE: SHP,Nasdaq: SHPGY), the global specialty biopharmaceutical company, todayannounced the launch of a 13-city mobile screening initiative for adults withAttention Deficit Hyperactivity Disorder (ADHD), a psychiatric disorder thataffects approximately 4.4 percent of the U.S. adult population aged 18-44according to the National Comorbidity Survey Replication, a nationallyrepresentative household survey. The screening initiative, launched inAtlanta, GA, is designed to help raise awareness that ADHD is not just achildhood disorder. Research shows it is estimated that up to 65 percent ofchildren with ADHD will continue to exhibit symptoms into adulthood. Adultswho think they may have ADHD can take the first step toward recognizing thesymptoms of the disorder by answering the 6-question World Health Organization(W.H.O.) adult ADHD screener. The screening initiative, known as the "RoADHDTrip," is housed, transported and anchored by the RoADHD Trip Tractor Trailerwhich expands into a tented area housing eight self-screening stations.

"Shire developed this mobile screening initiative as a forum to educatethe public about ADHD in adults and provide information and resources toindividuals about this disorder," said Gerardo Torres, M.D., Vice Presidentand Scientific Lead, of Shire's ADHD Business Unit. "This programdemonstrates Shire's on-going commitment to providing information for thosewho may be struggling with the symptoms of ADHD."

In each of the 13 cities, Shire is partnering with the Attention DeficitDisorder Association (ADDA), a leading adult ADHD patient advocacyorganization, in an effort to assist up to 20,000 adults to self-screen forthis disorder. Volunteers from ADDA will also be on-site to answer questionsabout ADHD in adults and to provide information about their organization. TheW.H.O. adult ADHD screener, a questionnaire that is used to help recognize thesymptoms of ADHD, will be available via on-site computers to help facilitateself evaluations. The W.H.O. screener is not designed to provide a diagnosisof ADHD but may provide information to participants regarding the symptoms ofADHD. Participants should discuss any questions they have regarding theW.H.O. screener results and other concerns about ADHD with their physician.

"Seeking information and speaking to qualified health care professionalsare critical steps to diagnosis and management of ADHD," further explained Dr.Torres. "This initiative is an important first step to encourage thatdialogue between patients and their physicians."

The symptoms of ADHD may lead to potentially serious consequences inadults. Surveys have shown that when compared with their non-ADHD peers,adults with ADHD may be:

Adults who think they may have ADHD are invited to participate in a freeself-screening when Shire's ADHD "RoADHD Trip," arrives in their area. Theevents will take in Atlanta, GA; Alpharetta, GA; Raleigh, NC; Simpsonville,SC; Albany, NY; Nashville, TN; York, PA; Boston, MA; Chicago, IL; Milwaukee,WI; Taylor, MI; Ionia, MI; and Columbus, OH.

To find out specific dates of each of the screening events and for ADHDinformation in general, please visit www.ADHDSupport.com or ADD.org.

About ADHD

ADHD is one of the most common psychiatric disorders in children andadolescents. Approximately 7.8 percent of all school-aged children, or about4.4 million U.S. children aged 4 to 17 years, have been diagnosed with ADHD atsome point in their lives, according to the U.S. Centers for Disease Controland Prevention (CDC). The disorder is also estimated to affect 4.4 percent ofU.S. adults aged 18-44 based on results from the National Comorbidity SurveyReplication, a nationally representative household survey, which used alay-administered diagnostic interview to assess a wide range of DSM-IVdisorders. ADHD is a neurobiologica

Latest Press Release on General News

Precision oncology company Flindr Therapeutics announces €20 million Series A financing to advance first-in-class small molecule inhibitors

V-Bio Ventures leads international syndicate which includes Johnson & Johnson Innovation – JJDC, Inc., QBIC Fund, Flanders Future Tech Fund, Curie Capital as well as seed investor...

Rett Syndrome Research Trust Partners with Vivalink to Shift Symptom Assessment Paradigms in Rett Syndrome

Vivalink's remote patient monitoring solutions accelerate research into rare neurological disorder CAMPBELL, Calif. , April 23, 2024 /PRNewswire/ -- Vivalink , a leading pro...

World IBS Day - April 19th: Raising Awareness for Everyone with IBS

Debunking myths about Irritable Bowel Syndrome TORONTO , April 18, 2024 /PRNewswire/ -- IBS is a chronic gastrointestinal disorder with symptoms like abdominal pain, bloating,...

Important step taken on the Canada Disability Benefit in Budget 2024, but funding falls short

More work must be done to lift Canadians with disabilities out of poverty TORONTO , April 17, 2024 /CNW/ - The federal government has taken an important step on the Canada Di...

Hydrinity Accelerated Skin Science Introduces MicroFusion Technology and Expands Facial Skincare Line with PRELUDE Facial Treatment Cleanser and HYDRI-C Vitamin C Moisturizer

The Next Generation Technology with the Power to Transform Skin MONROE, La. , April 15, 2024 /PRNewswire/ -- Hydrinity Accelerated Skin Science announced today the launch of t...